Beyond bronchodilators and T2 biologics: what is in the pipeline for severe asthma and COPD
- Asthma care has moved from β2-agonists and inhaled corticosteroids to combination inhalers and then to biologics for Type 2-high severe disease.
- COPD has gained better bronchodilators but little that treats inflammation or lung remodelling.
- The narrative review surveys agents in testing and argues that failed trials expose how little is understood about disease subtypes and responders.
💡 Points Based on the abstract
The most useful line is the one about failed trials: many were probably right drugs in unselected patients. For anyone picking a target here, the question is which biomarker enriches the responders before Phase 2, particularly in non-T2 COPD where the field lacks a validated endotype. Remodelling endpoints also need to be measurable in months, not years.
📄 Paper · British Journal of Pharmacology ↗ New anti-inflammatory and remodelling drugs for unmet clinical needs in severe asthma and chronic obstructive pulmonary disease (COPD)